Condition
Advanced Solid Malignancies
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 8 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesNCT07223047 · 2025-11-25
RECRUITINGStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesNCT05417594 · 2022-06-24
RECRUITINGAn Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.NCT03084471 · 2017-06-05
COMPLETEDA Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid MalignanciesNCT02740985 · 2016-06-17
COMPLETEDPhase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid TumoursNCT02260661 · 2014-11-01
COMPLETEDA Phase I Dose Escalation Study of Erlotinib in Combination With TheophyllineNCT02080078 · 2014-09-01
TERMINATEDInvestigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung CancerNCT01605916 · 2012-06-01
COMPLETEDA Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.NCT01219543 · 2010-11-01
TERMINATEDCommon interventions
[11C]AZ1419 3391DRUG1Abiraterone AcetateDRUG1AZD1480 BIDDRUG1AZD1480 DailyDRUG1AZD4635DRUG1AZD6244DRUG1AZD8835DRUG1AZD8835 in combination with fulvestrantDRUG1AZD9574DRUG1BMS-986523DRUG1CetuximabDRUG1Datopotamab Deruxtecan (Dato-DXd)DRUG1DocetaxelDRUG1DurvalumabDRUG1EnzalutamideDRUG1ErlotinibDRUG1GemcitabineDRUG1MEDI4736 (Durvalumab)BIOLOGICAL1MEDI4736 (Durvalumab) + TremelimumabBIOLOGICAL1Nab-PaclitaxelDRUG1OleclumabDRUG1PembrolizumabDRUG1Temozolomide (TMZ)DRUG1TheophyllineDRUG1Trastuzumab Deruxtecan (T-DXd)DRUG1
Leading sponsors
Trial status mix
COMPLETED4
RECRUITING2
TERMINATED2
Phase mix
PHASE17
PHASE22
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.